Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients
Evaluation of the Individual Early Psychoeducation Program for Schizophrenic Disorders in Inpatients: A Randomized, Multicenter Trial
University Hospital, Tours
200 participants
Jun 17, 2022
INTERVENTIONAL
Conditions
Summary
Schizophrenia affects about 0.7% of the population. Poor insight, which is common in this disease, linked to poor drug compliance is leads to rehospitalisation with major impact on quality of life. Indeed, many patients relapse with exacerbation of symptoms. Psychoeducation can improve therapeutic alliance and medication compliance. In this context, an individual psycho-education program (PEPITS) has been developed. PEPITS carried out by nurses during the initial stages of hospitalisation. The hypothesis is that PEPITS program will decrease relapse and improve the compliance and insight and and so the quality of life.
Eligibility
Inclusion Criteria8
- Age between 18 and 65 years
- Patient with a diagnosed and reported schizophrenic disorder announced :
- Schizophrenia
- Schizoaffective disorder
- Or a diagnosed and reported Delusional Disorder
- Express written consent by the participant after receiving information about the study
- Be able to communicate verbally
- Participant affiliated to a social security scheme
Exclusion Criteria4
- Pregnant or breastfeeding woman
- Patient who does not speak French
- Participation in a psycho-education group in the last 2 years
- Patient under legal protection or guardianship
Interventions
The programme has three main phases: Phase I: Introduction phase (Session 1) Phase II: Pathology and care work phase (Sessions 2 - 3 - 4) Phase III: Recovery and "stepping stone" phase (Sessions 5 - 6 - 7) The programme provides information, keys and new skills to the patient through 3 phases focusing on pathology and recovery.
Patients will receive the same psychiatric care as the experimental group except of the PEPITS programme.
Locations(11)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05329363